Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilobelimab versus placebo for ulcerative pyoderma gangrenosum
2023-506250-20-00Phase 3Completed
- Sponsor
- InflaRx
- Start
- Dec 2023
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of riliprubart in pyoderma gangrenosum (PG) (2 arms), sponsored by InflaRx. Primary endpoint: Complete closure of the target ulcer by end of treatment. Started Dec 2023; status: completed.
02
Drugs
riliprubart
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on 2023-506250-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506250-20-00.